Summary
4.52 0.17(3.80%)07/05/2024
Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc (ABEO)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
4.03 | 6.74 | -0.66 | -39.31 | -20.23 | 3.79 | -96.04 | -100.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 4.52 | |
Open | 4.40 | |
High | 4.55 | |
Low | 4.29 | |
Volume | 336,788 | |
Change | 0.18 | |
Change % | 4.03 | |
Avg Volume (20 Days) | 268,772 | |
Volume/Avg Volume (20 Days) Ratio | 1.25 | |
52 Week Range | 2.83 - 9.01 | |
Price vs 52 Week High | -49.89% | |
Price vs 52 Week Low | 59.54% | |
Range | 2.61 | |
Gap Up/Down | 0.03 |
Fundamentals | ||
Market Capitalization (Mln) | 186 | |
EBIDTA | -45,912,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 19.50 | |
Book Value | 0.5590 | |
Earnings Per Share | -2.5300 | |
EPS Estimate Current Quarter | -0.4700 | |
EPS Estimate Next Quarter | -0.5100 | |
EPS Estimate Current Year | -2.1400 | |
EPS Estimate Next Year | -1.9000 | |
Diluted EPS (TTM) | -2.5300 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | -13.7714 | |
Return on asset (TTM) | -0.4699 | |
Return on equity (TTM) | -2.6060 | |
Revenue TTM | 3,500,000 | |
Revenue per share TTM | 0.1640 | |
Quarterly Revenue Growth (YOY) | -1.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -28,001,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 13.9303 | |
Revenue Enterprise Value | 45.6299 | |
EBITDA Enterprise Value | -3.1580 | |
Shares | ||
Shares Outstanding | 40,848,800 | |
Shares Float | 19,043,756 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.13 | |
Insider (%) | 3.56 | |
Institutions (%) | 48.96 |
06/09 12:00 EST - accesswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
06/07 14:40 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
06/03 07:30 EST - globenewswire.com
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
05/28 07:30 EST - globenewswire.com
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference.
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference.
05/15 07:30 EST - globenewswire.com
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended our cash runway into 2026, well beyond anticipated regulatory milestones,” said Vish Seshadri, Chief Executive Officer of Abeona.
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended our cash runway into 2026, well beyond anticipated regulatory milestones,” said Vish Seshadri, Chief Executive Officer of Abeona.
05/03 07:30 EST - globenewswire.com
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.
05/02 17:50 EST - seekingalpha.com
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB. Pz-cel has shown higher efficacy than the competition in treating larger skin lesions in RDEB. Despite receiving a complete response letter from the FDA, Abeona believes the manufacturing issues can be resolved and plans to submit a response by Q3 this year.
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB. Pz-cel has shown higher efficacy than the competition in treating larger skin lesions in RDEB. Despite receiving a complete response letter from the FDA, Abeona believes the manufacturing issues can be resolved and plans to submit a response by Q3 this year.
05/01 20:32 EST - businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) investors concerning the Company's possible violations of federal securities laws. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatment, pz-cel, stating that “the FDA noted that certain additional information.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) investors concerning the Company's possible violations of federal securities laws. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatment, pz-cel, stating that “the FDA noted that certain additional information.
04/29 19:11 EST - businesswire.com
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatme.
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatme.
04/23 17:20 EST - seekingalpha.com
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
Abeona Therapeutics Inc. stock dropped by over half after receiving a Complete Response Letter from the FDA regarding its Biologics License Application for pz-cel. The FDA identified manufacturing issues that need to be resolved, delaying the potential approval of pz-cel. However, no issues were raised regarding efficacy and safety, nor are more trials required. Despite the setback, Abeona Therapeutics may present a buying opportunity as it bottoms out, with estimated peak revenue of over $500 million in the U.S. assuming approval.
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
Abeona Therapeutics Inc. stock dropped by over half after receiving a Complete Response Letter from the FDA regarding its Biologics License Application for pz-cel. The FDA identified manufacturing issues that need to be resolved, delaying the potential approval of pz-cel. However, no issues were raised regarding efficacy and safety, nor are more trials required. Despite the setback, Abeona Therapeutics may present a buying opportunity as it bottoms out, with estimated peak revenue of over $500 million in the U.S. assuming approval.
04/23 08:53 EST - investorplace.com
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
Abeona Therapeutics (NASDAQ: ABEO ) stock is falling on Tuesday after getting a Complete Response Letter ( CRL ) from the Food and Drug Administration (FDA). The CRL from the FDA notes that the regulator needs additional Chemistry Manufacturing and Controls ( CMC ) information from Abeona Therapeutics.
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
Abeona Therapeutics (NASDAQ: ABEO ) stock is falling on Tuesday after getting a Complete Response Letter ( CRL ) from the Food and Drug Administration (FDA). The CRL from the FDA notes that the regulator needs additional Chemistry Manufacturing and Controls ( CMC ) information from Abeona Therapeutics.
04/22 16:31 EST - reuters.com
US FDA declines to approve Abeona's skin disorder treatment
Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition.
US FDA declines to approve Abeona's skin disorder treatment
Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition.
04/22 16:05 EST - globenewswire.com
Abeona Therapeutics Provides Regulatory Update on Pz-cel
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and submitting requested CMC information in 3Q 2024 Conference call and webcast on Tuesday, April 23, 2024 at 8:30 a.m. ET to provide details on the requested CMC information CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced a regulatory update for prademagene zamikeracel (pz-cel).
Abeona Therapeutics Provides Regulatory Update on Pz-cel
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and submitting requested CMC information in 3Q 2024 Conference call and webcast on Tuesday, April 23, 2024 at 8:30 a.m. ET to provide details on the requested CMC information CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced a regulatory update for prademagene zamikeracel (pz-cel).